All In Biotech

Drug Trial Radar · NCT07845513

A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity

A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PF-08653944 FOLLOWING SINGLE DOSE SUBCUTANEOUS ADMINISTRATION IN OTHERWISE HEALTHY CHINESE ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

11

Actual

Start

Oct 13, 2026

Primary completion

Feb 21, 2027

Study completion Feb 21, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about: * How PF-08653944 is changed and removed from the body after taken * Safety of PF-08653944 * The extent to which side effects can be tolerated after taking PF- 08653944 for the possible treatment of heart failure This study is seeking participants who: * Are healthy Chinese adults who are aged 18 years and older * Have body mass index of 24 - 45 kilograms/meter2 * Have a total body weight of equal to or more than 50 kilograms (110 pounds) * Do not have prior significant medical conditions, history of drug or alcohol abuse All participants in this study will receive a single dose of PF-08653944 at the study clinic. The experiences of the participants receiving the study medicine will be looked at. This will help to see if the study medicine is safe. Participants will take part in this study for around 16 weeks. During this time, they will have 6 study visits at the study clinic.

Conditions

  • Overweight
  • Obesity
  • Healthy Adults

Interventions

  • PF-08653944Drug

    Solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of PF-08653944Time frame: Up to 85 days
  2. PK: Maximum Observed Concentration (Cmax) of PF-08653944Time frame: Up to 85 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.